RESUMEN
Sickle cell disease (SCD) is a major medical problem in which mono-therapeutic interventions have so far shown only limited effectiveness. We studied the repurpose of genistein, which could prevent sickle hemoglobin from polymerizing under hypoxic conditions in this disease. Genistein an important nutraceutical molecule found in soybean. The present study examines the repurposing genistein as an anti- sickling agent. Genistein shows inhibition of Hb S polymerization as well as a sickle reversal. Also, we have explored the interaction of the genistein with sickle hemoglobin (Hb S), using fluorescence, far-UV-CD spectroscopy, MicroScale Thermophoresis (MST), FTIR, combined with molecular modeling computations. The quenching constant decreases with increasing temperature, a characteristic that coincides with the static type of quenching mechanism. Temperature-dependent fluorescence measurements and molecular modeling studies reveal that apart from the hydrogen bonding, electrostatic interactions also play a crucial role in genistein and Hb S complex formation. In silico, distribution prediction of adsorption, digestion, metabolism, excretion, and toxicity (ADME/Tox) based on physical and chemical properties show that genistein is nontoxic and has ideal drug properties. The helicity and thermophoretic mobility of Hb S was a change in the presence of genistein, which leads to the destabilizing the Hb S polymer was examined using CD and MST, respectively. Our results open up the possibility for a promising therapeutic approach for the SCD by repurposed genistein as an anti-sickling agent.Communicated by Ramaswamy H. Sarma.
Asunto(s)
Anemia de Células Falciformes , Hemoglobina Falciforme , Anemia de Células Falciformes/tratamiento farmacológico , Reposicionamiento de Medicamentos , Genisteína/farmacología , Hemoglobina Falciforme/química , Humanos , Análisis EspectralRESUMEN
Sickle cell disease is an inherited disease caused by point mutation in hemoglobin (ß-globin gene). Under oxygen saturation, sickle hemoglobin form polymers, leading to rigid erythrocytes. The transition of the blood vessels is altered and initiated by the adhesion of erythrocytes, neutrophils and endothelial cells. Sickle Hemoglobin (HbS) polymerization is a major cause in red blood cells (RBC), promoting sickling and destruction of RBCs. Isoquercitrin, a medicinal bioactive compound found in various medicinal plants, has multiple health benefits. The present study examines the potential of isoquercitrin as an anti-sickle agent, showing a significant decrease in the rate of polymerization as well as sickling of RBCs. Isoquercitrin-induced graded alteration in absorbance and fluorescence of HbS, confirmed their interaction. A negative value of ΔG° strongly suggests that it is a spontaneous exothermic reaction induced by entropy. Negative ΔH° and positive ΔS° predicted that hydrogen and hydrophobic binding forces interfered with a hydrophobic microenvironment of ß6Val leading to polymerization inhibition of HbS. HbS-Isoquercitrin complex exhibits helical structural changes leading to destabilization of the HbS polymer as confirmed by CD spectroscopy. MST and DSC results indicate greater changes in thermophoretic mobility and thermal stability of sickle hemoglobin in the presence of isoquercitrin, respectively. These findings were also supported by molecular simulation studies using DOCK6 and GROMACS. Hence, we can conclude that isoquercitrin interacts with HbS through hydrogen bonding, which leads to polymerization inhibition. Consequently, isoquercitrin could potentially be used as a medication for the treatment of sickle cell disease.Communicated by Ramaswamy H. Sarma.
Asunto(s)
Antidrepanocíticos , Células Endoteliales , Hemoglobina Falciforme/genética , Quercetina/análogos & derivados , Análisis EspectralRESUMEN
Polymerization of hemoglobin S is a major cause of morbidity and mortality in sickle cell disease, which leads to sickling and destruction of red blood cell. Alizarin, a bioactive compound from Rubia cordifolia, is reported to be blood purifier. This study investigates the potential of alizarin as an anti-sickling agent, showing a significant decrease in the rate of polymerization, therefore inhibiting the rate of sickling with increasing concentration. Interaction studies indicated that the fluorescence intensity of sickle hemoglobin (Hb S) decreases gradually with increasing alizarin concentration. This suggests the static quenching, where binding constant and the number of binding sites were deduced at different temperatures. The negative values of Gibbs energy change (ΔG0) strongly suggest that it is entropy-driven spontaneous and exothermic reaction. Negative enthalpy (ΔH0) and positive entropy (ΔS0) stipulated that hydrogen and hydrophobic bonding forces were interfering in a hydrophobic micro-environment of ß6Val leading to Hb S polymerization inhibition. In circular dichroism (CD) spectra, Hb S in the presence of alizarin shows helical structural changes leading to destabilization of Hb S polymer. These findings were also supported by molecular docking simulation studies using DOCK6 and GROMACS. So, from these findings, we may conclude that alizarin interacts with Hb S through hydrogen bonding and leading to inhibition of Hb S polymerization. Consequently, alizarin may have potential use as an anti-sickle cell medication for sickle cell disorder. Communicated by Ramaswamy H. Sarma.
Asunto(s)
Antraquinonas/metabolismo , Hemoglobina Falciforme/metabolismo , Modelos Moleculares , Análisis Espectral , Adulto , Antraquinonas/química , Muerte Celular/efectos de los fármacos , Celulosa/análogos & derivados , Celulosa/química , Dicroismo Circular , Eritrocitos/metabolismo , Hemoglobina Falciforme/química , Humanos , Enlace de Hidrógeno , Ligandos , Simulación de Dinámica Molecular , Fragilidad Osmótica , Polimerizacion , Estructura Secundaria de Proteína , Espectrometría de Fluorescencia , Espectrofotometría Ultravioleta , Termodinámica , Adulto JovenRESUMEN
The paper explained the microencapsulation of three different antigenic materials viz. Diphtheria toxoid (DT), whole cell pertussis antigens (PT and FHA) and tetanus toxoid (TT) by coacervation method using water soluble chitosan as a polymer crosslinked by vanillin/TPP co-crosslinkers for the development of oral trivalent DwPT vaccine. Instrumental characterization of chitosan microspheres suggested specific interaction with vanillin/TPP, higher thermal stability, amorphous nature, spherical morphology with size less than 2µm along with positive charge density offering mucoadhesive properties. Furthermore, PT and FHA showed higher encapsulation up to 94% followed by TT and DT. Cumulative release rate of DT was (68.47%), TT (73.67%), PT (43%) and FHA (53%). Release kinetics interpreted using DD solver program, indicated protein release followed first order kinetics and obeyed Korsmeyer-peppas model, stating fickian diffusion relates to diffusion, erosion and controlled release rate of the encapsulated toxoids. Application of formulations on caco-2 cell line showed negligible cytotoxic effect and efficient uptake of FITC labelled microspheres. The obtained in-vivo results suggests that the final trivalent DwPT formulation were having successful elicitation of both systemic (IgG) and mucosal (sIgA) immune response in balb/c mice. Overall studies indicated that DwPT formulation could be a suitable alternative to available injectable DaPT vaccine.
Asunto(s)
Quitosano/química , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/inmunología , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/farmacología , Composición de Medicamentos , Agua/química , Adhesividad , Adsorción , Animales , Células CACO-2 , Muerte Celular , Reactivos de Enlaces Cruzados/química , Liberación de Fármacos , Fluoresceína-5-Isotiocianato/metabolismo , Humanos , Inmunidad Mucosa/efectos de los fármacos , Intestinos/inmunología , Cinética , Masculino , Ratones Endogámicos BALB C , Microesferas , Mucinas/química , Tamaño de la Partícula , Saliva/inmunología , Espectrometría por Rayos X , Espectroscopía Infrarroja por Transformada de Fourier , Electricidad Estática , Sus scrofa , Temperatura , Difracción de Rayos XRESUMEN
In drug delivery research, several toxic chemical crosslinkers and non-toxic ionic crosslinkers have been exploited for the synthesis of microparticles from acetic acid soluble chitosan. This paper hypothesized the implementation of sodium potassium tartrate (SPT) as an alternative crosslinker for sodium tripolyphosphate (TPP) and SPT/TPP co-crosslinkers for synthesis of the microparticles using water soluble chitosan (WSC) for encapsulation of Bovine serum albumin (BSA) as a model protein, and Tetanus toxoid (TT) as a model vaccine. The crosslinking was confirmed by FT-IR, SEM with EDS. The XRD entailed molecular dispersion of proteins and thermal analysis confirmed the higher stability of STP/TPP co-crosslinked formulations. The resultant microparticles were exhibiting crosslinking degree (52-67%), entrapment efficiency (72-80%), particle size (0.3-1.7µm), zeta potential (+24 to 46mV) and mucoadhesion (41-68%). The superiority of SPT over TPP was confirmed by higher crosslinking degree and entrapment efficiency. However, co-crosslinking were advantageous in higher regression values for Langmuir adsorption isotherm, slower swelling tendency and extended 30days controlled in-vitro release study. TT release obeyed the Quasi-Fickian diffusion mechanism for single and cocrosslinked formulations. Overall, in crosslinking of chitosan as biological macromolecules, STP/TPP may be alternative for single ionic crosslinked formulations for protein antigen delivery.
Asunto(s)
Antígenos Bacterianos/química , Quitosano/química , Reactivos de Enlaces Cruzados/química , Polifosfatos/química , Albúmina Sérica Bovina/química , Tartratos/química , Toxoide Tetánico/química , Animales , Bovinos , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Albúmina Sérica Bovina/farmacocinética , Toxoide Tetánico/farmacocinéticaRESUMEN
Microspheres were prepared from water soluble chitosan using dual vanillin/TPP crosslinkers. Placebo (C1), Bovine serum albumin (BSA) (C2), monovalent tetanus toxoid (TT) (C3) and divalent tetanus (TT) and diphtheria toxoids (DT) (C4) encapsulated microspheres were studied in terms of size (1-4 µm), encapsulation efficiency (75-80%), swelling and mucoadhesion (56-68%). FT-IR, TGA, XRD and SEM characterization of microspheres suggested specific interaction, more thermal stability, amorphous nature and rough surfaces of encapsulated microspheres. EDS confirmed the co-crosslinking and ninhydrin tests were showing higher crosslinking density. Zeta potential was 47.7 to 66.2 +mV indicating the potential stability of the colloidal system. Equilibrium adsorption isotherms described encapsulated microspheres followed the Langmuir isotherm model, suggesting monolayer adsorption of the mucin on microspheres. In-vitro release studies up to four weeks indicated zero order kinetics and obeyed swelling-controlled super case II transport release mechanism. Thus, the present study could be helpful in developing the multivalent oral vaccine.
Asunto(s)
Antígenos/química , Benzaldehídos/química , Quitosano/química , Toxoide Diftérico/química , Polifosfatos/química , Toxoide Tetánico/química , Adhesividad , Microesferas , Mucinas/química , Albúmina Sérica Bovina/químicaRESUMEN
Multidrug resistance (MDR) in cancer is a phenomenon in which administration of a single chemotherapeutic agent causes cross-resistance of cancer cells to a variety of therapies even with different mechanisms of action. Development of MDR against standard therapies is a major challenge in the treatment of cancer. Previously we have demonstrated a unique ability of CXL017 (5) to selectively target MDR cancer cells and synergize with mitoxantrone (MX) in HL60/MX2 MDR cells. Here we expand its scope and demonstrate that 5 can synergize with both vincristine and paclitaxel in three different MDR cell lines (HL60/DNR, K562/HHT300, and CCRF-CEM/VLB100). We also demonstrate that 5 has potent cytotoxicity in the NCI-60 panel of cell lines with an average IC(50) of 1.04 µM. In addition, 5 has a unique mechanism of action in comparison with standard agents in the NCI database based on COMPARE analysis. Further structure-activity relationship study led to the development of a more potent analogue, compound 7d, with an IC(50) of 640 nM in HL60/MX2. Additionally, one enantiomer of 5 is 13-fold more active than the less active enantiomer. Taken together, our study has led to the discovery of a series of analogues that selectively target drug-resistant cancer cells with the potential for the treatment of drug-resistant cancers.
Asunto(s)
Benzopiranos/química , Benzopiranos/farmacología , Resistencia a Múltiples Medicamentos/efectos de los fármacos , Resistencia a Antineoplásicos/efectos de los fármacos , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Daunorrubicina/farmacología , Sinergismo Farmacológico , Células HCT116 , Células HL-60 , Células HT29 , Humanos , Concentración 50 Inhibidora , Células K562 , Mitoxantrona/farmacología , Estructura Molecular , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Paclitaxel/farmacología , Estereoisomerismo , Relación Estructura-Actividad , Vincristina/farmacologíaRESUMEN
Rapid development of multiple drug resistance against current therapies is a major barrier in the treatment of cancer. Therefore, anticancer agents that can overcome acquired drug resistance in cancer cells are of great importance. Previously, we have demonstrated that ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4H-chromene-3-carboxylate (5a, sHA 14-1), a stable analogue of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (6, HA 14-1), mitigates drug resistance and synergizes with a variety of cancer therapies in leukemia cells. Structure-activity relationship (SAR) studies of 5a guided the development of ethyl 2-amino-6-(3',5'-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (5q, CXL017), a compound with low micromolar cytotoxicity against a wide-range of hematologic and solid tumor cells. More excitingly, our studies of 5q in camptothecin (CCRF-CEM/C2) and mitoxantrone (HL-60/MX2) resistant cancer cells highlight its ability to selectively kill drug-resistant cells over parent cancer cells. 5q inhibits tumor cell growth through the induction of apoptosis, with detailed mechanism of its selectivity toward drug-resistant cancer cells under investigation. These results suggest that 5q is a promising candidate for treatment of cancers with multiple drug resistance.
Asunto(s)
Benzopiranos/química , Benzopiranos/farmacología , Resistencia a Antineoplásicos/efectos de los fármacos , Apoptosis/efectos de los fármacos , Camptotecina/farmacología , Línea Celular Tumoral , Humanos , Leucemia/tratamiento farmacológico , Mitoxantrona/farmacología , Relación Estructura-ActividadRESUMEN
HA 14-1, a small-molecule antagonist against anti-apoptotic Bcl-2 proteins, was demonstrated to induce selective cytotoxicity toward malignant cells and to overcome drug resistance. Due to its poor stability and the reactive oxygen species (ROS) generated by its decomposition, chemical modification of HA 14-1 is needed for its future development. We have synthesized a stabilized analog of HA 14-1--sHA 14-1, which did not induce the formation of ROS. As expected from a putative antagonist against anti-apoptotic Bcl-2 proteins like HA 14-1, sHA 14-1 disrupted the binding interaction of a Bak BH3 peptide with Bcl-2 or Bcl-X(L) protein, inhibited the growth of tumor cells through the induction of apoptosis, and circumvented the drug resistance induced by the over-expression of anti-apoptotic Bcl-2 and Bcl-X(L) proteins. Interestingly, the impairment of extrinsic apoptotic pathway induced moderate resistance to sHA 14-1. The moderate resistance suggested that sHA 14-1 generated part of its apoptotic stress through the intrinsic pathway, possibly through its antagonism against anti-apoptotic Bcl-2 proteins. The resistance indicated that sHA 14-1 generated apoptotic stress through the extrinsic apoptotic pathway as well. The ability of sHA 14-1 to induce apoptotic stress through both pathways was further supported by the synergism of sHA 14-1 towards the cytotoxicities of Fas ligand and dexamethasone in Jurkat cells. Taken together, these findings suggest that sHA 14-1 may represent a promising candidate for the treatment of drug-resistant cancers either as a monotherapy or in combination with current cancer therapies.
Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Benzopiranos/farmacología , Resistencia a Antineoplásicos , Leucemia/tratamiento farmacológico , Nitrilos/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Benzopiranos/uso terapéutico , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Sinergismo Farmacológico , Proteína Ligando Fas/metabolismo , Humanos , Concentración 50 Inhibidora , Células Jurkat , Leucemia/metabolismo , Leucemia/patología , Nitrilos/uso terapéutico , Fragmentos de Péptidos/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Transfección , Proteína bcl-X/antagonistas & inhibidores , Proteína bcl-X/genética , Proteína bcl-X/metabolismoRESUMEN
Overexpressing antiapoptotic Bcl-2 proteins to suppress apoptosis is one major mechanism via which cancer cells acquire drug resistance against cancer therapy. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4 H-chromene-3-carboxylate (HA 14-1) is one of the earliest small-molecule antagonists against antiapoptotic Bcl-2 proteins. Since its discovery, HA 14-1 has been shown to be able to synergize a variety of anticancer agents. HA 14-1 also could selectively eliminate tumor cells with elevated level of Bcl-2 protein. HA 14-1, therefore, is being intensely investigated as a potential anticancer agent. Previous reports of HA 14-1 implied that it may not be stable, raising the question of whether HA 14-1 is a suitable drug candidate. The potential stability also raised the concern about whether HA 14-1 is the bioactive species. In this report, we confirm that HA 14-1 is not stable under physiological conditions: it rapidly decomposes in RPMI cell culture medium with a half-life of 15 min. This decomposition process also generates reactive oxygen species (ROS). To identify the actual candidate(s) for the observed bioactivity of HA 14-1, we characterized the structures, quantified the amount, and evaluated the bioactivities of the decomposed products. We also used ROS scavengers to explore the function of ROS. From these studies, we established that none of the decomposition products could account for the bioactivity of HA 14-1. ROS generated during the decomposition process, however, are critical for the in vitro cytotoxicity and the apoptosis induced by HA 14-1. This study demonstrates that HA 14-1 is not stable under physiological conditions and that HA 14-1 can generate ROS through its decomposition, independent of Bcl-2 antagonism. Because of its intrinsic tendency to decompose and to generate ROS, caution should be taken in using HA 14-1 as a qualified antagonist against antiapoptotic Bcl-2 proteins.
Asunto(s)
Apoptosis/efectos de los fármacos , Benzopiranos/metabolismo , Benzopiranos/farmacología , Medio de Cultivo Libre de Suero/farmacología , Nitrilos/metabolismo , Nitrilos/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/antagonistas & inhibidores , Especies Reactivas de Oxígeno/metabolismo , Animales , Benzopiranos/química , Humanos , Nitrilos/química , Especies Reactivas de Oxígeno/químicaRESUMEN
Systemic and local immune response against Chitosan encapsulated tetanus toxoid (CS-TT) microparticles is studied, prepared by ionic cross-linking using Sodium Tripolyphosphate (STPP). Final formulation was evaluated in terms of release of TT in 0.1 N HCl and PBS (pH 7.4), sedimentation profile and stability. CS-TT microparticles, TT in PBS and plain CS microparticles were orally administered to mice and TT (adsorbed) was administered through intramuscular route. Sera were analyzed for anti-TT IgG and intestinal lavage, faeces, intestinal washings for anti-TT IgA levels using an ELISA. Entrapment efficiency of about 100% was obtained. A dose dependent immune response was observed in mice vaccinated with Chitosan-TT microparticles. A strong enhancement of the systemic and local immune response against TT were found when compared with oral feeding of TT in PBS. The study shows the efficacy of chitosan microparticle suspension system, containing a high molecular protein (TT), in inducing the IgA in intestine and IgG in systemic circulation. This demonstrates that chitosan microparticles can prove to be a promising oral vaccine delivery system for mucosal and systemic immunity.
Asunto(s)
Quitosano/administración & dosificación , Toxoide Tetánico/administración & dosificación , Administración Oral , Animales , Relación Dosis-Respuesta Inmunológica , Sistemas de Liberación de Medicamentos , Concentración de Iones de Hidrógeno , Ratones , Ratones Endogámicos BALB C , Microesferas , Tamaño de la Partícula , Conformación Proteica , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Toxoide Tetánico/química , Toxoide Tetánico/inmunología , Vacunación , ViscosidadRESUMEN
The present study describes response of a bacterial strain isolated from a polluted river to heavy metal toxicity. The bacterium was identified to be Klebsiella pneumoniae by biochemical tests using API 20E strips and 16S ribotyping. The isolate was studied for its tolerance to two heavy metals, i.e., cobalt (Co(2+)) and lead (Pb(2+)) by growing it in citrate mineral medium (CMM). Proteomic approach involving two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and mass spectrometry (MS) was used to identify the differentially expressed proteins under heavy metal stress. Two of the differentially expressed proteins were identified to be l-isoaspartate protein carboxymethyltransferase type II and DNA gyrase A. To our knowledge, this is for the first time that K. pneumoniae has been reported to be present in metal contaminated site and l-isoaspartate protein carboxymethyltransferase type II protein to be over expressed under heavy metal stress. The role of these proteins in metal tolerance is discussed.
Asunto(s)
Proteínas Bacterianas/análisis , Farmacorresistencia Bacteriana , Metales Pesados/metabolismo , Proteómica/métodos , Ríos/microbiología , Secuencia de Bases , Cobalto/metabolismo , Klebsiella pneumoniae/crecimiento & desarrollo , Klebsiella pneumoniae/aislamiento & purificación , Klebsiella pneumoniae/metabolismo , Plomo/metabolismo , Pruebas de Sensibilidad Microbiana , Datos de Secuencia Molecular , Mapeo Peptídico , ARN Ribosómico 16S/química , Contaminantes Químicos del Agua/metabolismoRESUMEN
The structure-activity relationship studies of ethyl 2-amino-6-cyclopentyl-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (1, HA 14-1), an antagonist of the antiapoptotic Bcl-2 proteins, are reported. A series of analogues of 1 with varied functional groups at the 6-position of the chromene ring were synthesized. These candidates were evaluated for their binding interactions with three antiapoptotic proteins: Bcl-2, Bcl-XL, and Bcl-w. They were also assayed for their in vitro cytotoxicities against a set of Jurkat cells with varied levels of Bcl-2 and Bcl-XL proteins and a non-small-cell lung carcinoma cell line (NCI-H460). It was found that the 6-bromo of 1 was not essential for its bioactivity and the 6-position can accommodate a variety of alkyl groups. 1 and its analogues bind to all of the three antiapoptotic Bcl-2 proteins tested. Positive correlations were observed between the binding affinities of these candidates to the antiapoptotic Bcl-2 proteins and their in vitro cytotoxicities, suggesting that the antiapoptotic Bcl-2 proteins are likely to be the cellular targets of 1 and its analogues. (In this study, the binding interactions of the small molecules to antiapoptotic Bcl-2 proteins were studied by assaying their abilities to compete against a Bak peptide binding to the antiapoptotic Bcl-2 proteins. Inhibitory constants, instead of dissociation constants, were obtained in such assays. The term "binding affinity" is used in this article for simplicity.) The most active compound, 3g, had a >3-fold increase of binding affinity to the antiapoptotic Bcl-2 proteins and a >13-fold increase of in vitro cytotoxicity over 1. Though Jurkat cells with transgenic overexpression of Bcl-2 or Bcl-XL protein can develop resistance to standard cancer therapies, such cells failed to develop resistance to 1 based candidates. 1 also sensitizes Jurkat cells to cisplatin. These studies provide further support that 1 and its analogues function as antagonists for antiapoptotic Bcl-2 proteins and that they have the potential, either as a single agent or as a combination therapy with other anticancer agents, to treat cancers with the overexpression of antiapoptotic Bcl-2 proteins.